Besides ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and match ample to tolerate FCR therapy, may still be very good candidates to the latter, With all the reward getting this cure can be concluded in 6 months whilst ibrutinib should be taken indefinitely. This feature could well be specially beneficial for non-compliant patients o